C83-C30

Diffuse large B-cell lymphoma, unspecified site

## Overview of Diffuse Large B-cell Lymphoma (DLBCL) Unspecified Site Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive non-Hodgkin lymphoma (NHL), accounting for approximately 30-40% of all NHL cases. It is characterized by the rapid, clonal proliferation of large, atypical B-lymphocytes that have lost their normal differentiation pathways. The term 'unspecified site' (C83.30) is used when the primary anatomical location of the lymphoma is not specified in the clinical documentation or is unclear. This diagnosis signifies the presence of DLBCL without pinpointing a specific lymph node region or extranodal organ involvement. ### Etiology and Risk Factors The exact cause of DLBCL is often unknown. However, several risk factors have been identified, including immunodeficiency states (e.g., HIV/AIDS, immunosuppression post-organ transplant), certain viral infections (Epstein-Barr virus, Human Herpesvirus 8), autoimmune diseases, and prior exposure to chemotherapy or radiation therapy. Genetic mutations and chromosomal translocations, particularly involving _MYC_, _BCL2_, and _BCL6_ genes, are central to its pathogenesis. ### Clinical Presentation DLBCL typically presents as a rapidly enlarging, often painless, mass, most commonly in lymph nodes (e.g., neck, axilla, groin). However, it can also arise in extranodal sites, including the gastrointestinal tract, skin, bone, central nervous system, and testes. About 30% of patients present with extranodal disease. Systemic symptoms, known as 'B symptoms' (unexplained fever, drenching night sweats, and unintentional weight loss), are present in about one-third of patients and indicate advanced disease. ### Diagnosis Diagnosis relies on an excisional biopsy of the affected tissue, followed by histopathological examination and immunohistochemistry. Flow cytometry, cytogenetics, and molecular studies (e.g., FISH, next-generation sequencing) are crucial for confirming the B-cell lineage, identifying specific genetic alterations, and distinguishing DLBCL from other lymphomas or reactive conditions. Staging involves PET/CT scans, bone marrow biopsy, and sometimes lumbar puncture, to determine the extent of disease. ### Treatment and Prognosis Treatment for DLBCL is typically aggressive and curative intent, primarily involving combination chemotherapy. The standard first-line regimen is R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). For patients with localized disease, combined modality therapy with chemotherapy and radiation therapy may be considered. For relapsed or refractory disease, high-dose chemotherapy with autologous stem cell transplantation, CAR T-cell therapy, or novel targeted agents are options. Prognosis varies depending on factors such as age, stage, performance status, presence of B symptoms, and molecular subtype, as assessed by the International Prognostic Index (IPI). Despite its aggressive nature, a significant proportion of patients with DLBCL can achieve long-term remission or cure with modern treatment strategies.

Clinical Symptoms

Rapidly growing painless lymphadenopathy (swollen lymph nodes)
B symptoms: unexplained fever (typically >100.4°F or 38°C), drenching night sweats, unexplained weight loss (>10% of body weight in 6 months)
Fatigue or malaise
Loss of appetite
Pruritus (itching)
Symptoms related to extranodal involvement (e.g., abdominal pain, nausea, vomiting, GI bleeding if in gastrointestinal tract; neurological symptoms if in CNS; bone pain if in bone)

Common Causes

Generally unknown (idiopathic) in many cases
Immunodeficiency (e.g., HIV/AIDS, post-organ transplant immunosuppression, congenital immunodeficiency syndromes, autoimmune diseases)
Certain viral infections (e.g., Epstein-Barr virus (EBV), Human Herpesvirus 8 (HHV-8) in specific subtypes)
Chronic inflammation (e.g., Helicobacter pylori infection in gastric DLBCL)
Genetic predisposition and chromosomal abnormalities (e.g., translocations involving _MYC_, _BCL2_, _BCL6_ genes)
Exposure to certain environmental toxins (less clear evidence for some pesticides, solvents)
Prior treatment with chemotherapy or radiation therapy (can increase risk of secondary malignancies including lymphoma)

Documentation & Coding Tips

Always specify the anatomical site(s) of Diffuse Large B-cell Lymphoma (DLBCL) if known, rather than using 'unspecified site' (C83.30). Detailed site information (e.g., nodal, extranodal, primary mediastinal) significantly enhances coding accuracy and reflects clinical specificity.

Example: POOR DOCUMENTATION: 'Pt with DLBCL. Started R-CHOP.' IMPROVED DOCUMENTATION: '68 y.o. male with newly diagnosed Stage III Diffuse Large B-cell Lymphoma, confirmed by excisional biopsy of a right cervical lymph node (primary site: cervical lymph nodes, multiple). PET scan shows extensive nodal involvement in cervical, axillary, and inguinal regions, with extranodal involvement of the gastric wall and bone marrow infiltration. Patient reports B symptoms (fevers, night sweats, 10lb unintentional weight loss over 2 months). Initiating cycle 1 of R-CHOP today. Performance status ECOG 1. Labs show anemia of chronic disease. Plan: Aggressive chemotherapy, close monitoring for tumor lysis syndrome and febrile neutropenia.'

Billing Focus: Specifying the anatomical site(s) (e.g., cervical, gastric, bone marrow) allows for more precise ICD-10 coding (e.g., C83.31-C83.39 series, and codes for extranodal sites). This directly supports medical necessity for site-specific imaging (CT/PET), biopsies, and targeted treatments. Documenting 'multiple sites' or specific extranodal involvement justifies higher complexity E&M services.

Clearly document the current status of the lymphoma (e.g., newly diagnosed, in active treatment, in remission, relapsed, refractory) and any associated complications of the disease or its treatment. This provides a complete clinical picture and supports appropriate coding.

Example: POOR DOCUMENTATION: 'Pt with DLBCL, here for chemo.' IMPROVED DOCUMENTATION: '55 y.o. female with Diffuse Large B-cell Lymphoma, primary mediastinal (C83.32), diagnosed 6 months ago. Currently undergoing Cycle 4 of R-CHOP. Today presents with fatigue, mild nausea, and oral mucositis (K12.1), grade 2, attributed to current chemotherapy regimen. Labs show ANC 800, platelets 90,000, indicative of chemotherapy-induced pancytopenia (D70.1, D69.59). No fever or signs of infection. Disease remains active, but patient is tolerating treatment with expected side effects. Discussed symptom management and importance of infection precautions.'

Billing Focus: Documenting active treatment (chemotherapy administration codes, Z51.11) and specific complications (e.g., mucositis, pancytopenia with specific ICD-10 codes, and adverse effects of antineoplastic drugs T45.1X5A) supports medical necessity for specific interventions, follow-up visits, and medication management. It also justifies higher complexity E&M services.

Thoroughly document all relevant systemic symptoms (B symptoms), extranodal involvement, and comorbidities. These details provide crucial clinical context and impact both billing and risk adjustment.

Example: POOR DOCUMENTATION: 'Pt with DLBCL follow-up.' IMPROVED DOCUMENTATION: '72 y.o. male with known Diffuse Large B-cell Lymphoma, primary gastric (C83.35), diagnosed 1 year ago. Currently in partial remission (Z85.79 for history of other malignant neoplasms) following R-CHOP. Presenting today for routine follow-up. Reports ongoing fatigue and chronic anemia secondary to malignancy (D63.0), requiring oral iron supplementation. Also manages controlled Type 2 Diabetes Mellitus with neuropathy (E11.40). No fevers, night sweats, or significant weight loss since last visit. PET scan 2 weeks ago showed stable partial remission. Plan: Continue surveillance, monitor anemia, optimize diabetic control. Discussed potential for maintenance rituximab.'

Billing Focus: Documenting comorbidities like anemia (D63.0), Type 2 Diabetes with complications (E11.40), and linking them to the malignancy or general health status, supports higher complexity E&M coding. The history of malignancy (Z85.79) is critical for post-treatment follow-up and justifies ongoing surveillance.

Relevant CPT Codes

99205 - Office or other outpatient visit, new patient, level 5
Initial diagnosis of DLBCL often involves extensive history taking, comprehensive physical examination, review of complex diagnostic studies (biopsies, imaging), and high-complexity medical decision making to determine treatment strategy and staging. This supports the highest level E&M for new patients.
99215 - Office or other outpatient visit, established patient, level 5
Established patients with DLBCL undergoing active treatment, managing severe complications, or experiencing relapse often require extensive evaluation and complex medical decision making, justifying a high-level E&M code.
96413 - Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
DLBCL treatment commonly involves multi-agent chemotherapy regimens like R-CHOP, requiring intravenous administration of cytotoxic drugs.
96417 - Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)
Many chemotherapy regimens for DLBCL involve infusions lasting several hours, necessitating billing for additional time.
38221 - Bone marrow biopsy, needle or trocar
Bone marrow involvement is common in DLBCL and a bone marrow biopsy is crucial for staging and prognosis.
38555 - Excision of deep lymph node(s) in neck, axilla, or groin
Excisional lymph node biopsy is the gold standard for definitive diagnosis of lymphoma, requiring surgical removal of a suspect lymph node.
88305 - Surgical pathology, gross and microscopic examination, Level IV
Biopsies for lymphoma diagnosis require detailed pathological examination, including special stains and molecular studies, typically billed at a higher complexity level.
88342 - Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure
Immunohistochemistry is critical for subtyping lymphoma and differentiating DLBCL from other lymphoid neoplasms and reactive processes.
78815 - PET imaging, whole body; with concurrently acquired CT for attenuation correction and anatomic localization
PET/CT is standard for staging DLBCL at diagnosis, assessing response to treatment, and detecting relapse.